Cagrilintide OXY-CAGRI (15 mg) OxyPharma

Catalogue entry: Cagrilintide OXY-CAGRI OxyPharma. Labelled content: 15 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Cagrilintide is a long-acting amylin analogue investigated in appetite and weight-management research. Its target system differs from the incretin receptors addressed by Semaglutide or Tirzepatide. The distinction matters when reading results from single-compound studies and from combinations such as cagrilintide plus semaglutide.

What the research measured

Lau and colleagues published a phase II weight-management trial in The Lancet in 2021. Garvey and colleagues later reported REDEFINE 1 in the New England Journal of Medicine in 2025, examining a cagrilintide/semaglutide combination. Evidence for a specified combination cannot automatically be attributed to either ingredient alone or to a differently sourced mixture.

Sporting claims and limitations

Body-weight outcomes explain sporting interest, but they do not establish improved strength, endurance or recovery. Appetite effects and gastrointestinal symptoms are relevant trade-offs, particularly when training depends on adequate energy and protein intake. Long-term safety and applicability outside the studied populations require their own evidence. The number of active pathways does not determine product quality.

Product identity and documentation

This catalogue distinguishes the selected labelled content from any clinical administration schedule. Check that documentation specifies cagrilintide identity and whether the item contains a single compound or a declared combination. The actual lot, analytical methods and manufacturer reference should be traceable. A source photograph or trial name cannot establish equivalence to study material or authorisation of the supplied product.